Rosei E A, Brown J J, Lever A F, Robertson A S, Robertson J I, Trust P M
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):809-15.
1 Labetalol has been used as medical treatment in five patients with phaeochromocytoma. 2 In four of the five patients, blood pressure was satisfactorily controlled, and symptoms and signs were relieved. 3 Labetalol also provided satisfactory cover across surgery for the removal of tumours in two cases. 4 In one instance, it was not possible to give sufficient labetalol orally to suppress the attacks of phaeochromocytoma. This patient was not effectively controlled at operation with a combination of propranolol and phenoxybenzamine. 5 Intravenous labetalol rapidly lowered blood pressure and relieved symptoms in a patient experienced hypertensive crisis after clonidine withdrawal. 6 Labetalol is a useful addition to the medical treatment of phaeochromocytoma.
拉贝洛尔已用于5例嗜铬细胞瘤患者的药物治疗。
在这5例患者中的4例,血压得到了满意控制,症状和体征得以缓解。
拉贝洛尔在2例手术切除肿瘤的过程中也提供了满意的保障。
有1例,口服足量拉贝洛尔无法抑制嗜铬细胞瘤发作。该患者在手术中联合使用普萘洛尔和苯氧苄胺未能得到有效控制。
1例可乐定撤药后发生高血压危象的患者,静脉注射拉贝洛尔后血压迅速下降,症状缓解。
拉贝洛尔是嗜铬细胞瘤药物治疗中的一种有用补充药物。